In Good Company with Nicolai Tangen
GSK CEO: Drug Discovery, AI in Pharma, and Changing Company Culture
Apr 2, 2025
In this engaging discussion, Emma Walmsley, CEO of GSK and a key player in pharmaceuticals, shares insights on drug discovery and the integration of AI in speeding up medical advancements. She highlights GSK's breakthroughs in cancer treatments and respiratory medicine, while tackling the challenges of drug pricing and access. Emma also emphasizes the need for culture change within companies to foster innovation and accountability, and the significance of curiosity in leadership. Tune in for a captivating look at the future of healthcare!
54:51
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GSK's increasing emphasis on integrating AI and technology into drug discovery is reshaping the pharmaceutical landscape to expedite innovative therapies.
- Emma Walmsley highlights the importance of transforming company culture and prioritizing equitable access to healthcare alongside advances in medicine.
Deep dives
Advancements in Pharmaceutical Research
Significant excitement surrounds the integration of science and technology in pharmaceutical research, particularly in the quest to innovate for patient impact. The company has nearly doubled its R&D spending and anticipates five new drug and vaccine approvals this year, with a total of 14 expected to launch this decade. Notable innovations include antibody drug conjugates for treating multiple myeloma and treatments targeting diseases like hepatitis B, which affects 250 million people globally. These advancements represent a shift towards personalized medicine that not only enhances efficacy but also minimizes side effects.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
